Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) shares rose on Wednesday January 25 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock, boosting the price target of stock.
Meanwhile, the Dow Jones Industrial Average on Wednesday crossed the 20,000 level for the first time, while the S&P 500 and Nasdaq Composite also traded in record territory shortly after the market opened
The Dow Jones Industrial Average DJIA, +0.60% advanced 100 points, or 0.5%, to 20,012,
The S&P 500 index SPX, +0.55% gained 10 points, or 0.5%, to 2,289, with eight of the main 11 sectors trading higher.
The Nasdaq Composite index COMP, +0.66% was 30 points, or 0.6%, higher at 5,630.
All three main indexes set intraday records shortly after the opening bell.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) had its price target raised by equities researchers at HC Wainwright from $0.00 to $48.00. HC Wainwright currently has a rating of on the stock. The one-year price target of $48.83 is above the opening price of $41.75, that has caused a number of other analysts to report on the stock in recent days. Looking back over the last year, Pacira Pharmaceuticals, Inc. stock has a high of $66.32.
Yesterday Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) shares last traded at $39.20, a jump of $0.25 from the previous closing price. Opening at $41.75, they fluctuated from $38.55 and $41.80 throughout the day.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) now has a market cap of 1.47B.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) Average Daily Trading Volume
752,748 shares traded hands yesterday, 111 percent below normal, out of a total float 37,296,000. lower than normal. Look for trading volume to pick up in the coming days as swing traders often use upticks in trading volume to identify heavy volume accumulation or distribution by institutional investors.
As with all potential breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.
Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.
These instituitional investors have substantial teams of analysts that research thousands of stocks, so it is good validation to see them buying a stock you’re researching.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) Moving Averages
A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.
This is because the average acts like a floor (support), so the price bounces up off of it.
In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.
By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.
Trades for Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) have ranged from $29.95 – 66.32, and the stock now has a 50-day MA of $35.01 and 200-day MA of $36.61. Today’s last price is 40.89%% below the 52 week high of $66.32.
Earnings growth is a critical factor to consider when buying stocks and investors identify companies that have been successful at growing their earnings at least 25% or more for 3 consecutive years.
DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.